Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG...

Shares of Palatin Technologies Inc. PTN, +4.69% rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on

, +4.06% treatment for hypoactive sexual desire disorder triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for 's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 3. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

BringeReprobate

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Believing all this talk about a stock market bubble can land you in real troubleS&P 500 gains aren’t large enough to prove the market is overheated, writes Mark Hulbert.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »